|
1
|
World Health Organization: Breast Cancer.
https://www.who.int/news-room/fact-sheets/detail/breast-cancerJune
25–2024
|
|
2
|
Mo H, Yan X, Zhao F, Teng Y, Sun X, Lv Z,
Cao M, Zhao J, Song G, Pan B, et al: Association of taxane type
with patient-reported chemotherapy-induced peripheral neuropathy
among patients with breast cancer. JAMA Netw Open. 5:e22397882022.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hausheer FH, Schilsky RL, Bain S, Berghorn
EJ and Lieberman F: Diagnosis, management, and evaluation of
chemotherapy-induced peripheral neuropathy. Semin Oncol. 33:15–49.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tandon M, Yacur M, Brenin C and Dillon P:
Cryotherapy for prevention of chemotherapy induced peripheral
neuropathy in breast cancer. Crit Rev Oncol Hematol.
194:1042442024. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mustafa Ali M, Moeller M, Rybicki L and
Moore HCF: Long-term peripheral neuropathy symptoms in breast
cancer survivors. Breast Cancer Res Treat. 166:519–526. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zajączkowska R, Kocot-Kępska M, Leppert W,
Wrzosek A, Mika J and Wordliczek J: Mechanisms of
chemotherapy-induced peripheral neuropathy. Int J Mol Sci.
20:14512019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jordan B, Margulies A, Cardoso F,
Cavaletti G, Haugnes HS, Jahn P, Le Rhun E, Preusser M, Scotté F,
Taphoorn MJB, et al: Systemic anticancer therapy-induced peripheral
and central neurotoxicity: ESMO-EONS-EANO clinical practice
guidelines for diagnosis, prevention, treatment and follow-up. Ann
Oncol. 31:1306–1319. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Guijosa A, Freyria A, Espinosa-Fernandez
JR, Estrada-Mena FJ, Armenta-Quiroga AS, Ortega-Treviño MF, Catalán
R, Antonio-Aguirre B, Villarreal-Garza C and Perez-Ortiz AC:
Pharmacogenetics of taxane-induced neurotoxicity in breast cancer:
Systematic review and meta-analysis. Clin Transl Sci. 15:2403–2436.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Accordino MK, Lee S, Leu CS, Levin B,
Trivedi MS, Crew KD, Kalinsky K, Raghunathan R, Faheem K, Harden E,
et al: Randomized adaptive selection trial of cryotherapy,
compression therapy, and placebo to prevent taxane-induced
peripheral neuropathy in patients with breast cancer. Breast Cancer
Res Treat. 204:49–59. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ronconi G, Gatto DM, Codazza S, Ariani M,
Martire E, Cerretti L, Carella V, Coraci D, Ferriero G and Ferrara
PE: Conservative non-pharmacological treatments for
chemotherapy-induced peripheral neuropathies in women treated for
breast cancer: A systematic review. Eur J Phys Rehabil Med.
60:505–513. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schwab L and Visovsky C: Psychological
distress and quality of life in breast cancer survivors with
taxane-induced peripheral neuropathy: A scoping review. Front
Oncol. 12:10050832023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Barzaman K, Karami J, Zarei Z,
Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, Safari E and
Farahmand L: Breast cancer: Biology, biomarkers, and treatments.
Int Immunopharmacol. 84:1065352020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fitzpatrick JM and de Wit R: Taxane
mechanisms of action: Potential implications for treatment
sequencing in metastatic castration-resistant prostate cancer. Eur
Urol. 65:1198–1204. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jordan MA and Wilson L: Microtubules as a
target for anticancer drugs. Nat Rev Cancer. 4:253–265. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Moos PJ and Fitzpatrick FA: Taxanes
propagate apoptosis via two cell populations with distinctive
cytological and molecular traits. Cell Growth Differ. 9:687–697.
1998.PubMed/NCBI
|
|
16
|
McGrogan BT, Gilmartin B, Carney DN and
McCann A: Taxanes, microtubules and chemoresistant breast cancer.
Biochim Biophys Acta. 1785:96–132. 2008.PubMed/NCBI
|
|
17
|
Kang YJ, Yoon CI, Yang YJ, Baek JM, Kim
YS, Jeon YW, Rhu J, Yi JP, Kim D and Oh SJ: A randomized controlled
trial using surgical gloves to prevent chemotherapy-induced
peripheral neuropathy by paclitaxel in breast cancer patients (AIUR
trial). BMC Cancer. 23:5702023. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rivera DR, Ganz PA, Weyrich MS, Bandos H
and Melnikow J: Chemotherapy-associated peripheral neuropathy in
patients with early-stage breast cancer: A systematic review. J
Natl Cancer Inst. 110:djx1402018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bandos H, Melnikow J, Rivera DR, Swain SM,
Sturtz K, Fehrenbacher L, Wade JL III, Brufsky AM, Julian TB,
Margolese RG, et al: Long-term peripheral neuropathy in breast
cancer patients treated with adjuvant chemotherapy: NRG
oncology/NSABP B-30. J Natl Cancer Inst. 110:djx1622018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sparano JA, Wang M, Martino S, Jones V,
Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC and Davidson
NE: Weekly paclitaxel in the adjuvant treatment of breast cancer. N
Engl J Med. 358:1663–1671. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Salehifar E, Janbabaei G, Alipour A,
Tabrizi N and Avan R: Taxane-induced peripheral neuropathy and
quality of life in breast cancer patients. J Oncol Pharm Pract.
26:1421–1428. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dustin P: Microtubules. Springer Science
& Business Media; Heidelberg, Germany: pp. 4992012
|
|
23
|
Rowinsky EK, Cazenave LA and Donehower RC:
Taxol: A novel investigational antimicrotubule agent. J Natl Cancer
Inst. 82:1247–1259. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Komiya Y: Changes of fast axonal transport
by taxol injected subepineurally into the rat sciatic nerve.
Neurosci Res. 14:159–165. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Letourneau PC, Shattuck TA and Ressler AH:
Branching of sensory and sympathetic neurites in vitro is inhibited
by treatment with taxol. J Neurosci. 6:1912–1917. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Letourneau PC and Ressler AH: Inhibition
of neurite initiation and growth by taxol. J Cell Biol.
98:1355–1362. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vuorinen VS and Röyttä M: Taxol-induced
neuropathy after nerve crush: Long-term effects on regenerating
axons. Acta Neuropathol. 79:663–671. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Horwitz SB: Taxol (paclitaxel): Mechanisms
of action. Ann Oncol. 5 (Suppl 6):S3–S6. 1994.PubMed/NCBI
|
|
29
|
Persohn E, Canta A, Schoepfer S, Traebert
M, Mueller L, Gilardini A, Galbiati S, Nicolini G, Scuteri A,
Lanzani F, et al: Morphological and morphometric analysis of
paclitaxel and docetaxel-induced peripheral neuropathy in rats. Eur
J Cancer. 41:1460–1466. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sahenk Z, Barohn R, New P and Mendell JR:
Taxol neuropathy. Electrodiagnostic and sural nerve biopsy
findings. Arch Neurol. 51:726–729. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Weaver BA: How taxol/paclitaxel kills
cancer cells. Mol Biol Cell. 25:2677–2681. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pan Z, Avila A and Gollahon L: Paclitaxel
induces apoptosis in breast cancer cells through different
calcium-regulating mechanisms depending on external calcium
conditions. Int J Mol Sci. 15:2672–2694. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wanderley CW, Colón DF, Luiz JPM, Oliveira
FF, Viacava PR, Leite CA, Pereira JA, Silva CM, Silva CR, Silva RL,
et al: Paclitaxel reduces tumor growth by reprogramming
tumor-associated macrophages to an M1 Profile in a TLR4-dependent
manner. Cancer Res. 78:5891–5900. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gligorov J and Lotz JP: Preclinical
pharmacology of the taxanes: Implications of the differences.
Oncologist. 9 (Suppl 2):S3–S8. 2004. View Article : Google Scholar
|
|
35
|
Verweij J: Docetaxel (Taxotere): A new
anti-cancer drug with promising potential? Br J Cancer. 70:183–184.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Haldar S, Basu A and Croce CM: Bcl2 is the
guardian of microtubule integrity. Cancer Res. 57:229–233.
1997.PubMed/NCBI
|
|
37
|
Beretta GL, Cassinelli G, Rossi G,
Azzariti A, Corbeau I, Tosi D and Perego P: Novel insights into
taxane pharmacology: An update on drug resistance mechanisms,
immunomodulation and drug delivery strategies. Drug Resist Updat.
81:1012232025. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Vrignaud P, Semiond D, Benning V, Beys E,
Bouchard H and Gupta S: Preclinical profile of cabazitaxel. Drug
Des Devel Ther. 8:1851–1867. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Vrignaud P, Sémiond D, Lejeune P, Bouchard
H, Calvet L, Combeau C, Riou JF, Commerçon A, Lavelle F and Bissery
MC: Preclinical antitumor activity of cabazitaxel, a semisynthetic
taxane active in taxane-resistant tumors. Clin Cancer Res.
19:2973–2983. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Vredenburg MR, Ojima I, Veith J, Pera P,
Kee K, Cabral F, Sharma A, Kanter P, Greco WR and Bernacki RJ:
Effects of orally active taxanes on P-glycoprotein modulation and
colon and breast carcinoma drug resistance. J Natl Cancer Inst.
93:1234–1245. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jordan MA, Ojima I, Rosas F, Distefano M,
Wilson L, Scambia G and Ferlini C: Effects of novel taxanes
SB-T-1213 and IDN5109 on tubulin polymerization and mitosis. Chem
Biol. 9:93–101. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Koutras A, Zagouri F, Koliou GA, Psoma E,
Chryssogonidis I, Lazaridis G, Tryfonopoulos D, Kotsakis A, Res E,
Kentepozidis NK, et al: Phase 2 study of cabazitaxel as second-line
treatment in patients with HER2-negative metastatic breast cancer
previously treated with taxanes-a hellenic cooperative oncology
group (HeCOG) trial. Br J Cancer. 123:355–361. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Meyer-Wilmes P, Huober J, Untch M, Blohmer
JU, Janni W, Denkert C, Klare P, Link T, Rhiem K, Bayer C, et al:
Long-term outcomes of a randomized, open-label, phase II study
comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in
patients with triple-negative or luminal B/HER2-negative breast
cancer (GENEVIEVE). ESMO Open. 9:1030092024. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Beer M, Lenaz L and Amadori D; Ortataxel
Study Group, : Phase II study of ortataxel in taxane-resistant
breast cancer. J Clin Oncol. 26 (Suppl 15):S10662008. View Article : Google Scholar
|
|
45
|
Gornstein EL and Schwarz TL: Neurotoxic
mechanisms of paclitaxel are local to the distal axon and
independent of transport defects. Exp Neurol. 288:153–166. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Loprinzi CL, Lacchetti C, Bleeker J,
Cavaletti G, Chauhan C, Hertz DL, Kelley MR, Lavino A, Lustberg MB,
Paice JA, et al: Prevention and management of chemotherapy-induced
peripheral neuropathy in survivors of adult cancers: ASCO guideline
update. J Clin Oncol. 38:3325–3348. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Smith EML, Pang H, Cirrincione C,
Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C,
Le-Lindqwister N, et al: Effect of duloxetine on pain, function,
and quality of life among patients with chemotherapy-induced
painful peripheral neuropathy: A randomized clinical trial. JAMA.
309:1359–1367. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Aghili M, Taherioun M, Jafari F, Azadvari
M, Lashkari M, Kolahdouzan K, Ghalehtaki R and Abdshah A:
Duloxetine to prevent neuropathy in breast cancer patients under
paclitaxel chemotherapy (a double-blind randomized trial). Support
Care Cancer. 32:4932024.PubMed/NCBI
|
|
49
|
Hammack JE, Michalak JC, Loprinzi CL,
Sloan JA, Novotny PJ, Soori GS, Tirona MT, Rowland KM Jr, Stella PJ
and Johnson JA: Phase III evaluation of nortriptyline for
alleviation of symptoms of cis-platinum-induced peripheral
neuropathy. Pain. 98:195–203. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kautio AL, Haanpää M, Saarto T and Kalso
E: Amitriptyline in the treatment of chemotherapy-induced
neuropathic symptoms. J Pain Symptom Manage. 35:31–39. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Rao RD, Michalak JC, Sloan JA, Loprinzi
CL, Soori GS, Nikcevich DA, Warner DO, Novotny P, Kutteh LA and
Wong GY; North Central Cancer Treatment Group, : Efficacy of
gabapentin in the management of chemotherapy-induced peripheral
neuropathy: A phase 3 randomized, double-blind, placebo-controlled,
crossover trial (N00C3). Cancer. 110:2110–2118. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Shinde SS, Seisler D, Soori G, Atherton
PJ, Pachman DR, Lafky J, Ruddy KJ and Loprinzi CL: Can pregabalin
prevent paclitaxel-associated neuropathy?-An ACCRU pilot trial.
Support Care Cancer. 24:547–553. 2016.PubMed/NCBI
|
|
53
|
Najafi S, Heidarali Z, Rajabi M, Omidi Z,
Zayeri F, Salehi M and Haghighat S: Lithium and preventing
chemotherapy-induced peripheral neuropathy in breast cancer
patients: A placebo-controlled randomized clinical trial. Trials.
22:8352021. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Abouelmagd GMT, El-Karadawy SA, Ollo MMA,
Elwany YN, Mohamed ER and El-Amrawy WZ: Lidocaine infusion versus
duloxetine for prevention and management of taxane-induced
peripheral neuropathy among breast cancer patients-a randomized
controlled study. Pain Phys. 26:E497–E507. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
van der Wal SEI, van den Heuvel SAS,
Radema SA, van Berkum BFM, Vaneker M, Steegers MAH, Scheffer GJ and
Vissers KCP: The in vitro mechanisms and in vivo efficacy of
intravenous lidocaine on the neuroinflammatory response in acute
and chronic pain. Eur J Pain. 20:655–674. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Clifford DB, Simpson DM, Brown S, Moyle G,
Brew BJ, Conway B, Tobias JK and Vanhove GF; NGX-4010 C119 Study
Group, : A randomized, double-blind, controlled study of NGX-4010,
a capsaicin 8% dermal patch, for the treatment of painful
HIV-associated distal sensory polyneuropathy. J Acquir Immune Defic
Syndr. 59:126–133. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Simpson DM, Gazda S, Brown S, Webster LR,
Lu SP, Tobias JK and Vanhove GF; NGX-4010 C118 Study Group, :
Long-term safety of NGX-4010, a high-concentration capsaicin patch,
in patients with peripheral neuropathic pain. J Pain Symptom
Manage. 39:1053–1064. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Webster LR, Peppin JF, Murphy FT, Lu B,
Tobias JK and Vanhove GF: Efficacy, safety, and tolerability of
NGX-4010, capsaicin 8% patch, in an open-label study of patients
with peripheral neuropathic pain. Diabetes Res Clin Pract.
93:187–197. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Anand P, Elsafa E, Privitera R, Naidoo K,
Yiangou Y, Donatien P, Gabra H, Wasan H, Kenny L, Rahemtulla A and
Misra P: Rational treatment of chemotherapy-induced peripheral
neuropathy with capsaicin 8% patch: From pain relief towards
disease modification. J Pain Res. 12:2039–2052. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Barton DL, Wos EJ, Qin R, Mattar BI, Green
NB, Lanier KS, Bearden JD III, Kugler JW, Hoff KL, Reddy PS, et al:
A double-blind, placebo-controlled trial of a topical treatment for
chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA.
Support Care Cancer. 19:833–841. 2011.PubMed/NCBI
|
|
61
|
Gewandter JS, Mohile SG, Heckler CE, Ryan
JL, Kirshner JJ, Flynn PJ, Hopkins JO and Morrow GR: A phase III
randomized, placebo-controlled study of topical amitriptyline and
ketamine for chemotherapy-induced peripheral neuropathy (CIPN): A
University of Rochester CCOP study of 462 cancer survivors. Support
Care Cancer. 22:1807–1814. 2014.PubMed/NCBI
|
|
62
|
Ozdemir D, Arslan S, Artac M and
Karaarslan F: Topical menthol for chemotherapy-induced peripheral
neuropathy: A randomised controlled trial in breast cancer. BMJ
Support Palliat Care. 15:79–86. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Fallon MT, Storey DJ, Krishan A, Weir CJ,
Mitchell R, Fleetwood-Walker SM, Scott AC and Colvin LA: Cancer
treatment-related neuropathic pain: proof of concept study with
menthol-a TRPM8 agonist. Support Care Cancer. 23:2769–2777.
2015.PubMed/NCBI
|
|
64
|
Hanai A, Ishiguro H, Sozu T, Tsuda M, Yano
I, Nakagawa T, Imai S, Hamabe Y, Toi M, Arai H and Tsuboyama T:
Effects of cryotherapy on objective and subjective symptoms of
paclitaxel-induced neuropathy: Prospective self-controlled trial. J
Natl Cancer Inst. 110:141–148. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Tai HY, Lin LY, Huang TW and Gautama MSN:
Efficacy of cryotherapy in the prevention of chemotherapy-induced
peripheral neuropathy: A systematic review and meta-analysis.
Support Care Cancer. 32:4822024.PubMed/NCBI
|
|
66
|
Tsuyuki S, Senda N, Kanng Y, Yamaguchi A,
Yoshibayashi H, Kikawa Y, Katakami N, Kato H, Hashimoto T, Okuno T,
et al: Evaluation of the effect of compression therapy using
surgical gloves on nanoparticle albumin-bound paclitaxel-induced
peripheral neuropathy: A phase II multicenter study by the Kamigata
breast cancer study group. Breast Cancer Res Treat. 160:61–67.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Tsuyuki S, Yamagami K, Yoshibayashi H,
Sugie T, Mizuno Y, Tanaka S, Kato H, Okuno T, Ogura N, Yamashiro H,
et al: Effectiveness and safety of surgical glove compression
therapy as a prophylactic method against nanoparticle
albumin-bound-paclitaxel-induced peripheral neuropathy. Breast.
47:22–27. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Bandla A, Tan S, Kumarakulasinghe NB,
Huang Y, Ang S, Magarajah G, Hairom Z, Lim JSJ, Wong A, Chan G, et
al: Safety and tolerability of cryocompression as a method of
enhanced limb hypothermia to reduce taxane-induced peripheral
neuropathy. Support Care Cancer. 28:3691–3699. 2020.PubMed/NCBI
|
|
69
|
Binder J, Unver E, Clayton J, Burke P,
Paxman R, Sundar R and Bandla A: A Limb hypothermia wearable for
chemotherapy-induced peripheral neuropathy: A mixed-methods
approach in medical product development. Front Digit Health.
2:5732342020. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Bao T, Seidman AD, Piulson L, Vertosick E,
Chen X, Vickers AJ, Blinder VS, Zhi WI, Li Q, Vahdat LT, et al: A
phase IIA trial of acupuncture to reduce chemotherapy-induced
peripheral neuropathy severity during neoadjuvant or adjuvant
weekly paclitaxel chemotherapy in breast cancer patients. Eur J
Cancer. 101:12–19. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Yu B, Li M, Huang H, Ma S, Huang K, Zhong
Z, Yu S and Zhang L: Acupuncture treatment of diabetic peripheral
neuropathy: An overview of systematic reviews. J Clin Pharm Ther.
46:585–598. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Greenlee H, Crew KD, Capodice J, Awad D,
Buono D, Shi Z, Jeffres A, Wyse S, Whitman W, Trivedi MS, et al:
Randomized sham-controlled pilot trial of weekly
electro-acupuncture for the prevention of taxane-induced peripheral
neuropathy in women with early stage breast cancer. Breast Cancer
Res Treat. 156:453–464. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
D'Alessandro EG, Nagy DRN, de Brito CMM,
Almeida EPM, Battistella LR and Cecatto RB: Acupuncture for
chemotherapy-induced peripheral neuropathy: A randomised controlled
pilot study. BMJ Support Palliat Care. 12:64–72. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Iravani S, Kazemi Motlagh AH, Emami Razavi
SZ, Shahi F, Wang J, Hou L, Sun W, Afshari Fard MR, Aghili M,
Karimi M, et al: Effectiveness of acupuncture treatment on
chemotherapy-induced peripheral neuropathy: A pilot, randomized,
assessor-blinded, controlled trial. Pain Res Manag.
2020:25046742020. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Lu W, Giobbie-Hurder A, Freedman RA, Shin
IH, Lin NU, Partridge AH, Rosenthal DS and Ligibel JA: Acupuncture
for chemotherapy-induced peripheral neuropathy in breast cancer
survivors: A randomized controlled pilot trial. Oncologist.
25:310–318. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Molassiotis A, Suen LKP, Cheng HL, Mok
TSK, Lee SCY, Wang CH, Lee P, Leung H, Chan V, Lau TKH and Yeo W: A
Randomized assessor-blinded wait-list-controlled trial to assess
the effectiveness of acupuncture in the management of
chemotherapy-induced peripheral neuropathy. Integr Cancer Ther.
18:15347354198365012019. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Rostock M, Jaroslawski K, Guethlin C,
Ludtke R, Schröder S and Bartsch HH: Chemotherapy-induced
peripheral neuropathy in cancer patients: A four-arm randomized
trial on the effectiveness of electroacupuncture. Evid Based
Complement Alternat Med. 2013:3496532013. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Li K, Giustini D and Seely D: A systematic
review of acupuncture for chemotherapy-induced peripheral
neuropathy. Curr Oncol. 26:e147–e154. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Yeh ML, Liao RW, Yeh PH, Lin CJ and Wang
YJ: Acupuncture-related interventions improve chemotherapy-induced
peripheral neuropathy: A systematic review and network
meta-analysis. BMC Complement Med Ther. 24:3102024. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Coyne PJ, Wan W, Dodson P, Swainey C and
Smith TJ: A trial of scrambler therapy in the treatment of cancer
pain syndromes and chronic chemotherapy-induced peripheral
neuropathy. J Pain Palliat Care Pharmacother. 27:359–364. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Pachman DR, Weisbrod BL, Seisler DK,
Barton DL, Fee-Schroeder KC, Smith TJ, Lachance DH, Liu H, Shelerud
RA, Cheville AL and Loprinzi CL: Pilot evaluation of scrambler
therapy for the treatment of chemotherapy-induced peripheral
neuropathy. Support Care Cancer. 23:943–951. 2015.PubMed/NCBI
|
|
82
|
Smith TJ, Coyne PJ, Parker GL, Dodson P
and Ramakrishnan V: Pilot trial of a patient-specific cutaneous
electrostimulation device (MC5-A Calmare®) for
chemotherapy-induced peripheral neuropathy. J Pain Symptom Manage.
40:883–891. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Smith TJ, Razzak AR, Blackford AL,
Ensminger J, Saiki C, Longo-Schoberlein D and Loprinzi CL: A pilot
randomized sham-controlled trial of MC5-A scrambler therapy in the
treatment of chronic chemotherapy-induced peripheral neuropathy
(CIPN). J Palliat Care. 35:53–58. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Loprinzi C, Le-Rademacher JG, Majithia N,
McMurray RP, O'Neill CR, Bendel MA, Beutler A, Lachance DH,
Cheville A, Strick DM, et al: Scrambler therapy for chemotherapy
neuropathy: A randomized phase II pilot trial. Support Care Cancer.
28:1183–1197. 2020.PubMed/NCBI
|
|
85
|
Chung M, Chen TH, Wang XS, Kim KH and Abdi
S: The impact of scrambler therapy on pain and quality of life for
chemotherapy-induced peripheral neuropathy: A pilot study. Pain
Pract. 24:749–759. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Jennaro TS, Fang F, Kidwell KM, Smith EML,
Vangipuram K, Burness ML, Griggs JJ, Van Poznak C, Hayes DF, Henry
NL and Hertz DL: Vitamin D deficiency increases severity of
paclitaxel-induced peripheral neuropathy. Breast Cancer Res Treat.
180:707–714. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Chen CS, Zirpoli G, Barlow WE, Budd GT,
McKiver B, Pusztai L, Hortobagyi GN, Albain KS, Damaj MI, Godwin
AK, et al: Vitamin D insufficiency as a risk factor for
paclitaxel-induced peripheral neuropathy in SWOG S0221. J Natl
Compr Canc Netw. 21:1172–1180.e3. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Bosc L, Pero ME, Balayssac D, Jacquemot N,
Allard J, Suzanne P, Vollaire J, Cottet-Rousselle C, Michallet S,
Villaret J, et al: Preventing neuropathy and improving anti-cancer
chemotherapy with a carbazole-based compound. bioRxiv. Mar
13–2025.(Epub ahead of print).
|
|
89
|
Annamaraju P, Patel P and Baradhi KM:
Pentoxifylline. StatPearls. StatPearls Publishing; Treasure Island,
FL: 2025
|
